News

New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.

A study presented at SLEEP 2024 found melatonin increased sleep latency and overall sleep quality and decreased awakenings.

A late-breaking abstract from SLEEP 2024 shows the effect of mandibular devices on respiratory effort, and its overall impact on OSA.

An alternative device to CPAP shows clinical benefit and long-term patient adherence in new SLEEP 2024 trial data.

A study presented at SLEEP 2024 found persistent or progressive insomnia symptoms are linked to a greater depression risk than subthreshold cases with gradual improvement.

Healthcare professionals who were aware of the safety and efficacy of biosimilars were more likely to prescribe or switch patients to a biosimilar.

Diagnostic tests for anemia etiology are infrequently ordered, leading to a significant majority of patients with CKD receiving inadequate treatment.

Van der Kolk discusses the long-term outlook of MDMA in patients with PTSD and what further outcomes he'd like to see explored in the space.

A new study found a negative correlation between salivary rates and disease severity for patients with psoriasis.

A similar proportion of patients sustained baseline clinical status across treatment arms.

The FDA will decide on an application this summer for the treatment of PTSD with MDMA-assisted therapy. A renowned researcher explains how the treatment benefits patients with trauma.

At APA 2024, psychiatry experts shared their message to their colleagues for Mental Health Awareness Month.

Results from a Phase I trial showed significant LDL-C reduction with AZD0780 plus statin therapy in treatment-naive patients with hypercholesterolemia.

A new study found patients with psoriasis and depression have increased levels of C-reaction proteins and the erythrocyte sedimentation rate.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.

Statistically significant higher proportions of patients with CD or UC receiving subcutaneous CT-P13 achieved clinical remission compared with placebo.

At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.

At week 54, the clinical remission rate among patients receiving originator infliximab was 92.5% compared with 100% in the biosimilar CT-P13 group.

The new psychedelic CPT codes, effective January 1, 2024, could impact MDMA if approved. The FDA's Psychopharmacologic Drugs Advisory Committee will discuss MDMA on June 4.

New phase 2 trial data show more than double the patients receiving daily STS-01 1% cream achieved ≥30% improvement in SALT scores.

Announced on May 29, 2024, data from the MDD3001 trial indicate use of seltorexant was associated with meaningful improvements in depressive symptoms and sleep disturbances.

Blocking IL-33 production with statins may be an effective preventive strategy to suppress chronic inflammation and the development of certain cancers.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

Both the high-concentration and reference formulations of biosimilar adalimumab-adbm exhibited comparable pharmacokinetics and immunogenicity, with a similar safety profile.

Iron administration did not increase the mortality risk of hemodialysis patients with cancer, but the safety of increasing ESA doses was not confirmed.